Cite
Cumbo C, Impera L, Minervini CF, et al. Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients. Oncotarget. 2018;9(13):10978-10986doi: 10.18632/oncotarget.23971.
Cumbo, C., Impera, L., Minervini, C. F., Orsini, P., Anelli, L., Zagaria, A., Coccaro, N., Tota, G., Minervini, A., Casieri, P., Brunetti, C., Rossi, A. R., Parciante, E., Specchia, G., & Albano, F. (2018). Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients. Oncotarget, 9(13), 10978-10986. https://doi.org/10.18632/oncotarget.23971
Cumbo, Cosimo, et al. "Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients." Oncotarget vol. 9,13 (2018): 10978-10986. doi: https://doi.org/10.18632/oncotarget.23971
Cumbo C, Impera L, Minervini CF, Orsini P, Anelli L, Zagaria A, Coccaro N, Tota G, Minervini A, Casieri P, Brunetti C, Rossi AR, Parciante E, Specchia G, Albano F. Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients. Oncotarget. 2018 Jan 05;9(13):10978-10986. doi: 10.18632/oncotarget.23971. eCollection 2018 Feb 16. PMID: 29541390; PMCID: PMC5834283.
Copy
Download .nbib